Lexaria Bioscience Corp. LEXX Archives - Page 32 of 39

WednesdayJan 12, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022

Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industry DehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation DehydraTECH-CBD underwent three human clinical studies in 2021 that examined its ability to reduce arterial stiffness and blood pressure without creating unintended negative consequences A fourth, more comprehensive study was approved at year’s end, as the next step…

MondayJan 10, 2022 9:53 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet

Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study HYPER-H21-4 should "de-risk" outcomes prior to Lexaria's planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease Previous studies – HYPER-H21-1 and HYPER-H21-2 – have evidenced a remarkable, rapid, and safe drop in blood pressure with DehydraTECH-CBD A little less than two months after Lexaria Bioscience (NASDAQ: LEXX) announced…

ThursdayJan 06, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)

The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022 Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027 The advertising and media contract will allow SRAX to engage and manage social media companies for the creation and distribution of advertising materials promoting Lexaria Bioscience Lexaria Bioscience (NASDAQ: LEXX), an innovator of drug delivery platforms, announced that it will kick off 2022 with an advertising and media agreement with SRAX (NASDAQ:…

TuesdayJan 04, 2022 2:25 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time

As a significant number of drugs fail to reach the market owing to poor bioavailability, Lexaria Bioscience Corp. (NASDAQ: LEXX) is among those companies exploring different tools and methods to try to solve the problem. Lexaria is currently leading the industry in terms of innovation in drug delivery platforms. “Its patented DehydraTECH(TM) technology is specifically designed to improve how active pharmaceutical ingredients (‘APIs’) enter the bloodstream, ultimately increasing the effectiveness of fat-soluble molecules,” reads a recent article. The piece discusses Lexaria’s DehydraTECH as a product of years of research and millions in investments. Currently, the technology is covered by 23…

WednesdayDec 29, 2021 12:48 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board ("IRB") approval for its planned DehydraTECH-CBD human hypertension study HYPER-H21-4; the approval was received earlier than anticipated. The study is designed to "de-risk" outcomes prior to the company’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. The six-week study, which is entirely funded through the existing cash resources, is planned to include 60 volunteers, aged 45 to 70, using three 150 mg doses of DehydraTECH-CBD daily for the duration of the study. Dosing…

MondayDec 27, 2021 1:01 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients

Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure) The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients Lexaria recently announced that it is nearing completion of a third human study in which the company expects to further explore whether DehydraTECH-CBD successfully treats high pulmonary blood pressure A comprehensive six-week human clinical study is expected to begin soon Lexaria Bioscience (NASDAQ: LEXX) is nearing completion…

WednesdayDec 22, 2021 11:55 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD

In a recent human clinical trial, HYPER-H21-2, DehydraTECH™-CBD reduced arterial stiffness, potentially broadening Lexaria's application's ability to treat cardiovascular and other diseases beyond hypertension Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs The company has patent protection received for delivery of nicotine, vitamins, NSAIDs, terpenes and cannabinoids; and patents pending for delivery of estrogen, testosterone, PDE5 inhibitors, antiviral drugs and more Oral absorption is the most convenient and widely used administration route for taking medications. Decades of research have advanced…

TuesdayDec 21, 2021 2:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study…

FridayDec 17, 2021 9:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms as well as manage the flow of such media distributions. SRAX will employ leading-edge analytical algorithms in order to maximize engagement. “Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long…

FridayDec 17, 2021 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension

Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure) The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity HYPER-H21-2 results evidence…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX